Pharmaceuticals

Here's what Benzinga's reading on our friend, TheStreet.com. What's Hot On TheStreet Stocks Waver on Jobless Claims Stocks were mixed Thursday as a higher-than-expected rise in jobless claims took the shine off early earnings season momentum. The Dow Jones Industrial Average was down by 25...

ecently, Eli Lilly and Company (LLY) announced that the Gastrointestinal Drugs Advisory Committee of the US Food and Drug Administration (FDA) did not recommend the candidate- liprotamas' approval . Eli Lilly is seeking approval for the candidate to treat patients suffering from pancreatic...

Biogen Idec (BIIB) recently provided an update on its pipeline and "Framework for Growth" program at the J. P. Morgan Healthcare Conference.  Business Update Biogen had initially announced its "Framework for Growth" program in November 2010. With this program, Biogen is looking to streamline...

Biogen Idec (BIIB) recently provided an update on its pipeline and "Framework for Growth" program at the J. P. Morgan Healthcare Conference.  Business Update Biogen had initially announced its "Framework for Growth" program in November 2010. With this program, Biogen is looking to streamline...

ecently, Eli Lilly and Company (LLY) announced that the Gastrointestinal Drugs Advisory Committee of the US Food and Drug Administration (FDA) did not recommend the candidate- liprotamas' approval . Eli Lilly is seeking approval for the candidate to treat patients suffering from pancreatic...

Cubist Pharmaceuticals Inc.'s (CBST) preliminary revenues for the fourth quarter of 2010 declined 3% to $161.8 million due to the reduced sales of its antibiotic injection, Cubicin (daptomycin). Moreover, fourth quarter revenues were also hurt by the absence of service revenues pertaining to...

Cubist Pharmaceuticals Inc.'s (CBST) preliminary revenues for the fourth quarter of 2010 declined 3% to $161.8 million due to the reduced sales of its antibiotic injection, Cubicin (daptomycin). Moreover, fourth quarter revenues were also hurt by the absence of service revenues pertaining to...

Marketwatch has a list of five biotech stocks to own now, for a wide variety of reasons. The four names the author mentions are Cerus (NASDAQ: CERS), Curis (NASDAQ: CRIS), Compugen (NASDAQ: CGEN), Spectrum Pharmaceuticals (NASDAQ: SPPI), and Impax Laboratories (NASDAQ: IPXL). Regarding Cerus, the...

Sucampo Pharmaceuticals, Inc. (NASDAQ: SCMP) today announced that Jan Smilek, Chief Financial Officer and Vice President, Finance, has resigned, effective immediately, to pursue other opportunities. Sucampo will initiate search for a new CFO.

Morgan Stanley is lowering its 2011e EPS on Bristol-Myers Squibb (NYSE: BMY) from $2.30 to $2.23. “Our new EPS estimate is $0.02 below consensus,” Morgan Stanley writes. “We tweaked our model to reflect second-line ipilimumab launch in 3Q:11. Our 2011e probability-adjusted ipilimumab sales changed...

Merck & Co. Inc. (MRK) recently entered into an agreement with Parexel International Corporation (PRXL). Per the terms of the deal, Merck BioVentures (a division of Merck) will have access to Parexel's range of regulatory, strategic and clinical development planning capabilities for the...

Goldman Sachs rates Par Pharmaceutical (NYSE: PRX) Neutral with a PT of $34 today. In the report, Goldman Sachs states, "Our 12-month price target remains $34, balancing higher 2011 EPS against lower long-term estimates. Our price target is based on a combination of P/E (42.5%), EV/EBITDA (42.5%),...

Merck & Co. Inc. (MRK) recently entered into an agreement with Parexel International Corporation (PRXL). Per the terms of the deal, Merck BioVentures (a division of Merck) will have access to Parexel's range of regulatory, strategic and clinical development planning capabilities for the...

Novartis AG (NVS) recently received European approval for Lucentis to treat patients with certain forms of diabetic macular edema (DME). It is an eye condition related to long-standing diabetes that may lead to blindness, particularly in working-age population in most developed countries....

Novartis AG (NVS) recently received European approval for Lucentis to treat patients with certain forms of diabetic macular edema (DME). It is an eye condition related to long-standing diabetes that may lead to blindness, particularly in working-age population in most developed countries....